"Off The Leash" (OTL) Performance Blend

Tesamorelin + Ipamorelin + MOTS-C
Advanced Combination for Body Composition, Recovery & Cellular Energy

Formulation

Vial 1 – Tesamorelin + Ipamorelin

• 10mg Tesamorelin

• 3mg Ipamorelin

Vial 2 – MOTS-C

• 10mg MOTS-C

Two-vial protocol designed to allow independent timing of the GH-axis and mitochondrial components.

Classification: Prescription Only – Requires Provider Consultation & Approval

Why the OTL Performance Blend?

Because champions don’t hold back. The OTL Performance Blend combines three peptides with distinct physiological targets into one coordinated performance protocol.

Rather than placing all three compounds into a single vial, the updated OTL system uses two separate vials, allowing MOTS-C to be administered in the morning while Tesamorelin + Ipamorelin are administered before bed — or allowing both injections to be coordinated around training when appropriate.

• Tesamorelin – a growth hormone-releasing hormone analogue with human clinical evidence demonstrating reductions in visceral adipose tissue in studied populations. In a randomized 26-week trial involving adults with HIV-associated abdominal fat accumulation, tesamorelin significantly reduced visceral adipose tissue compared with placebo (Falutz et al., New England Journal of Medicine, 2007).

• Ipamorelin – a growth hormone secretagogue that stimulates endogenous GH release. Human pharmacokinetic/pharmacodynamic research demonstrated a dose-dependent GH response following ipamorelin administration (Gobburu et al., 1999).

• MOTS-C – a mitochondrial-derived peptide investigated for its role in metabolic signaling, skeletal muscle metabolism, AMPK activation, glucose utilization, and insulin sensitivity. Foundational research demonstrated improved metabolic homeostasis and insulin sensitivity, although much of this evidence comes from preclinical models (Lee et al., Cell Metabolism, 2015).

Together, the OTL protocol is designed around body composition, GH signaling, recovery, mitochondrial function, and metabolic performance while allowing each component to be timed according to its intended role.

💉 General Dosing Guidance (Based on 2mL Dilution = 200 Units Per Vial)

Standard Daily Protocol

Morning

• MOTS-C: 10 units

• Administered subcutaneously in the morning

Before Bed

• Tesamorelin + Ipamorelin: 10 units

• Administered subcutaneously before bed

Total Daily Administration: 20 units between the two injections

Alternative Pre-Workout Protocol

Both injections may alternatively be administered together immediately prior to training:

• 10 units Tesamorelin + Ipamorelin

• 10 units MOTS-C

• 20 total units administered between the two vials

This option consolidates the protocol around the training window rather than separating morning and nighttime administration.

📅 Recommended Protocol Options

1-Month Kickstart Protocol

• Tesamorelin + Ipamorelin: 10 units daily

• MOTS-C: 10 units daily

• Duration: 30 days

• Standard Timing: MOTS-C in the morning + Tesamorelin/Ipamorelin before bed

• Alternative Timing: Both 10-unit injections immediately prior to training

• Best For: Short introductory performance cycles, body-composition support, recovery, and metabolic optimization

• Evidence: Tesamorelin has randomized human clinical evidence supporting visceral adipose tissue reduction in its studied population, while MOTS-C has mechanistic and preclinical evidence supporting metabolic regulation.

3-Month Performance Protocol

• Tesamorelin + Ipamorelin: 10 units daily

• MOTS-C: 10 units daily

• Duration: 90 days

• Standard Timing: MOTS-C AM + Tesamorelin/Ipamorelin before bed

• Alternative Timing: Both injections immediately prior to training

• Best For: Sustained body-composition management, recovery support, metabolic performance, and structured performance programs

• Evidence: Human studies establish the GH-releasing activity of ipamorelin, while tesamorelin trials demonstrate sustained effects on visceral adipose tissue during continued treatment. MOTS-C research supports a potential role in skeletal-muscle and metabolic signaling, but its evidence base remains substantially more preclinical.

6-Month Comprehensive Performance Protocol

• Tesamorelin + Ipamorelin: 10 units daily

• MOTS-C: 10 units daily

• Initial Cycle: Up to 90 consecutive days

• Protocol Review: Provider reassessment following the initial 90-day treatment period before continuation

• Standard Timing: MOTS-C AM + Tesamorelin/Ipamorelin before bed

• Alternative Timing: Both injections immediately prior to training

• Best For: Longer-term body-composition, metabolic, recovery, and performance goals under provider supervision

• Evidence: Longer-duration tesamorelin research found continued reductions in visceral adipose tissue among participants remaining on treatment, while benefits diminished after discontinuation. These findings were specifically demonstrated in adults with HIV-associated abdominal fat accumulation and should not be generalized as proof of the complete OTL protocol.

📦 What’s Included With Every Order

• ✅ 1 x Tesamorelin + Ipamorelin vial
  10mg Tesamorelin + 3mg Ipamorelin

• ✅ 1 x MOTS-C vial
  10mg MOTS-C

• ✅ Pre-measured bacteriostatic water

• ✅ Insulin syringes + alcohol swabs

• ✅ Sharps disposal bag

• ✅ Printed dosing & administration guide

• ✅ Telehealth consultation + provider support

🌟 Summary

The Off The Leash (OTL) Performance Blend combines Tesamorelin, Ipamorelin, and MOTS-C into a flexible two-vial performance protocol.

The updated formulation separates Tesamorelin + Ipamorelin from MOTS-C, allowing the compounds to be timed according to their different physiological targets.

Standard Protocol:
10 units MOTS-C in the morning + 10 units Tesamorelin/Ipamorelin before bed.

Performance Alternative:
10 units of each vial administered together immediately prior to training — 20 total units.

The individual components have differing levels of scientific evidence: tesamorelin has substantial human clinical data in its approved/studied population, ipamorelin has human pharmacodynamic evidence demonstrating GH release, and MOTS-C remains supported predominantly by mechanistic and preclinical research. The complete OTL combination itself has not been established as an equivalent regimen in randomized clinical trials.

Get off the leash. Stay off the leash. Perform at your best.